Home Medicine Implementation and application of moving average as continuous analytical quality control instrument demonstrated for 24 routine chemistry assays
Article
Licensed
Unlicensed Requires Authentication

Implementation and application of moving average as continuous analytical quality control instrument demonstrated for 24 routine chemistry assays

  • Huub H. van Rossum EMAIL logo and Hans Kemperman
Published/Copyright: January 11, 2017

Abstract

Background:

General application of a moving average (MA) as continuous analytical quality control (QC) for routine chemistry assays has failed due to lack of a simple method that allows optimization of MAs. A new method was applied to optimize the MA for routine chemistry and was evaluated in daily practice as continuous analytical QC instrument.

Methods:

MA procedures were optimized using an MA bias detection simulation procedure. Optimization was graphically supported by bias detection curves. Next, all optimal MA procedures that contributed to the quality assurance were run for 100 consecutive days and MA alarms generated during working hours were investigated.

Results:

Optimized MA procedures were applied for 24 chemistry assays. During this evaluation, 303,871 MA values and 76 MA alarms were generated. Of all alarms, 54 (71%) were generated during office hours. Of these, 41 were further investigated and were caused by ion selective electrode (ISE) failure (1), calibration failure not detected by QC due to improper QC settings (1), possible bias (significant difference with the other analyzer) (10), non-human materials analyzed (2), extreme result(s) of a single patient (2), pre-analytical error (1), no cause identified (20), and no conclusion possible (4).

Conclusions:

MA was implemented in daily practice as a continuous QC instrument for 24 routine chemistry assays. In our setup when an MA alarm required follow-up, a manageable number of MA alarms was generated that resulted in valuable MA alarms. For the management of MA alarms, several applications/requirements in the MA management software will simplify the use of MA procedures.

  1. Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Research funding: None declared.

  3. Employment or leadership: H.H.R. is registered as the inventor on a filed patent describing the MA optimization and validation procedure applied. H.H.R. is owner and director of the Huvaros B.V. company that holds an exclusive license of the MA optimization and validation procedure applied.

  4. Honorarium: None declared.

  5. Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

References

1. Hoffmann RG, Waid ME. The “average of normals” method of quality control. Am J Clin Pathol 1965;43:134–41.10.1093/ajcp/43.2.134Search in Google Scholar PubMed

2. Kazmierczak SC. Laboratory quality control: using patient data to assess analytical performance. Clin Chem Lab Med 2003;41:617–27.10.1515/CCLM.2003.093Search in Google Scholar PubMed

3. Hinge M, Lund ED, Brandslund I, Plesner T, Madsen JS. Patient pools and the use of “patient means” are valuable tools in quality control illustrated by a bone-specific alkaline phosphatase assay. Clin Chem Lab Med 2016;54:403–6.10.1515/cclm-2015-0308Search in Google Scholar PubMed

4. Stepman HC, Stockl D, Stove V, Fiers T, Couck P, Gorus F, et al. Long-term stability of clinical laboratory data: sodium as benchmark. Clin Chem 2011;57:1616–7.10.1373/clinchem.2011.168195Search in Google Scholar PubMed

5. van Rossum HH, Kemperman H. A method for optimization and validation of moving average as continuous analytical quality control instrument demonstrated for creatinine. Clin Chim Acta 2016;457:1–7.10.1016/j.cca.2016.03.008Search in Google Scholar PubMed

6. van Rossum HH, Kemperman H. Optimization and validation of moving average quality control procedures using bias detection curves and moving average validation charts. Clin Chem Lab Med 2017;55:218–24.10.1515/cclm-2016-0270Search in Google Scholar PubMed

7. Bull BS, Elashoff RM, Heilbron DC, Couperus J. A study of various estimators for the derivation of quality control procedures from patient erythrocyte indices. Am J Clin Pathol 1974;61:473–81.10.1093/ajcp/61.4.473Search in Google Scholar PubMed

8. Cembrowski GS, Chandler EP, Westgard JO. Assessment of “average of normals” quality control procedures and guidelines for implementation. Am J Clin Pathol 1984;81:492–9.10.1093/ajcp/81.4.492Search in Google Scholar PubMed

9. Carey RN. Patient population controls. Clin Lab Med 2013;33:139–46.10.1016/j.cll.2012.11.002Search in Google Scholar PubMed

10. Ye JJ, Ingels SC, Parvin CA. Performance evaluation and planning for patient-based quality control procedures. Am J Clin Pathol 2000;113:240–8.10.1309/V5BT-BAWP-1WBF-14W6Search in Google Scholar PubMed

11. Fleming JK, Katayev A. Changing the paradigm of laboratory quality control through implementation of real-time test results monitoring: for patients by patients. Clin Biochem 2015;48:508–13.10.1016/j.clinbiochem.2014.12.016Search in Google Scholar PubMed

12. Available at: https://www.westgard.com/biodatabase1.htm. Accessed April 2016.Search in Google Scholar

13. Cembrowski GS. Thoughts on quality-control systems: a laboratorian’s perspective. Clin Chem 1997;43:886–92.10.1093/clinchem/43.5.886Search in Google Scholar

Received: 2016-8-5
Accepted: 2016-11-2
Published Online: 2017-1-11
Published in Print: 2017-7-26

©2017 Walter de Gruyter GmbH, Berlin/Boston

Articles in the same Issue

  1. Frontmatter
  2. Editorial
  3. Biomarkers of acute kidney injury: a step forward
  4. Reviews
  5. Biomarkers of acute kidney injury: the pathway from discovery to clinical adoption
  6. Prognostic value of glycated hemoglobin among patients with ST-segment elevation myocardial infarction: a systematic review and meta-analysis
  7. Opinion Paper
  8. Traceability in laboratory medicine: a global driver for accurate results for patient care
  9. Point
  10. To report or not to report: a proposal on how to deal with altered test results in hemolytic samples
  11. Counterpoint
  12. Reporting altered test results in hemolyzed samples: is the cure worse than the disease?
  13. Genetics and Molecular Diagnostics
  14. Early mixed hematopoietic chimerism detection by digital droplet PCR in patients undergoing gender-mismatched hematopoietic stem cell transplantation
  15. Comparison of Abbott RealTime genotype II, GeneMatrix restriction fragment mass polymorphism and Sysmex HISCL HCV Gr assays for hepatitis C virus genotyping
  16. General Clinical Chemistry and Laboratory Medicine
  17. The relationship between vacuum and hemolysis during catheter blood collection: a retrospective analysis of six large cohorts
  18. Evaluation of the Greiner Bio-One serum separator BCA Fast Clot tube
  19. Implementation and application of moving average as continuous analytical quality control instrument demonstrated for 24 routine chemistry assays
  20. Parathormone stability in hemodialyzed patients and healthy subjects: comparison on non-centrifuged EDTA and serum samples with second- and third-generation assays
  21. Association between plasma proANP and hyperuricemia in Chinese Han women: a cross-sectional study
  22. Activity of the liver enzyme ornithine carbamoyltransferase (OTC) in blood: LC-MS/MS assay for non-invasive diagnosis of ornithine carbamoyltransferase deficiency
  23. Detecting paraprotein interference on a direct bilirubin assay by reviewing the photometric reaction data
  24. Prediction of human iron bioavailability using rapid c-ELISAs for human plasma hepcidin
  25. Reference Values and Biological Variations
  26. Determination of glucose-6-phosphate dehydrogenase cut-off values in a Tunisian population
  27. Plasma levels of endothelin-1 and renal function among young and healthy adults
  28. Cancer Diagnostics
  29. A new strategy for calculating the risk of ovarian malignancy algorithm (ROMA)
  30. Laboratory characterization of leukemic cell procoagulants
  31. Diabetes
  32. Preparation, calibration and evaluation of the First International Standard for human C-peptide
  33. Hb variants in Korea: effect on HbA1c using five routine methods
  34. Letters to the Editor
  35. Pseudohyperkalemia in capillary whole-blood samples – an occasional error or a significant problem in a pediatric hospital?
  36. Elevation of creatine kinase is linked to disease severity and predicts fatal outcomes in H7N9 infection
  37. Analytical evaluation of point-of-care procalcitonin (PCT) and clinical performances in an unselected population as compared with central lab PCT assay
  38. Evaluation of an automated commercial ELISA method for calprotectin determination in pleural fluid
  39. The unfinished story of interference in thyroid hormones with Roche immunoassays: when prewashing procedures matter
  40. Effects of apixaban on prothrombin time, activated partial thromboplastin time and anti-Xa assays: a European survey
  41. Evaluation of a chemiluminescent immunoassay for urinary aldosterone on the DiaSorin LIAISON automated platform against RIA and LC-MS/MS
  42. Complex considerations when tendering for HbA1c analysers
Downloaded on 28.12.2025 from https://www.degruyterbrill.com/document/doi/10.1515/cclm-2016-0696/html
Scroll to top button